Aclaris Therapeutics upgraded to Buy from Hold at Jefferies

In This Article:

https://www.tipranks.com/news/the-fly/aclaris-therapeutics-upgraded-to-buy-from-hold-at-jefferies

Jefferies upgraded Aclaris Therapeutics (ACRS) to Buy from Hold with a price target of $7, up from $2. BSI-045B is the first anti-TSLP showing clinical proof of concept in atopic dermatitis, which is likely supported by a differentiated binding profile, the analyst tells investors in a research note. The firm says the data support further development in placebo-controlled study for additional validation in AD and beyond. If successful, BSI-045B could be the first anti-TSLP in the crowded AD space, providing a differentiated mechanism of actin improved efficacy and safety, contends Jefferies.

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on ACRS:

Waiting for permission
Allow microphone access to enable voice search

Try again.